Ovarian carcinosarcoma

Common Name(s)

Ovarian carcinosarcoma

Ovarian carcinosarcoma is a rare type of cancer impacting the ovaries. Cancer occurs when cells in a tissue or organ change and become abnormal. These cells begin to divide uncontrollably, damaging healthy cells in the process. Ovarian carcinosarcoma begins by affecting the ovaries, but if left untreated will aggressively spread to other parts of the body (metastasize). Carcinosarcoma is a mix of cancer of the epithelial cells (carcinoma), like the lining of organs, and cancer of connective tissues (sarcoma). Exactly how a carcinosarcoma begins to form is not well understood at this time. Ovarian carcinosarcoma accounts for less than 1-2% of all ovarian cancers.

Symptoms of ovarian carcinosarcoma may include bloating, swelling, and pelvic pain. Women who have been through menopause are more commonly affected. Other risk factors include obesity, using certain fertility medications, and hormone therapy. The risk increases the more one ovulates - meaning women who begin menstruation early or begin menopause late will have a higher risk of this type of cancer. Certain changes in genes, like BRCA1 and 2, may also increase your risk.

Diagnosis is made using imaging tests (ultrasounds and CT scans), blood tests, and testing a sample of the tumor (biopsy). Staging of the cancer depends on how far the cancer has spread. For example, Stage 1 means the cancer is only located in the ovaries; whereas Stage 4 means the cancer has spread beyond the abdomen. There is currently no cure for ovarian carcinosarcoma, and because the cancer is so rare, it is difficult to determine the best treatment. However, treatment options are available and early diagnosis is very important. Research is ongoing, so talk to your doctor and specialist(s) about the most current treatment options. Talk to a genetic counselor about possible genetic testing options. Support groups are also a good source of information and can connect you with other women affected by ovarian cancer.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Ovarian carcinosarcoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Ovarian carcinosarcoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Ovarian carcinosarcoma" returned 11 free, full-text research articles on human participants. First 3 results:

Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature.
 

Author(s): Melissa Brackmann, Marina Stasenko, Shitanshu Uppal, Jake Erba, R Kevin Reynolds, Karen McLean

Journal:

 

The optimal first-line chemotherapy for ovarian carcinosarcoma has not yet been determined. We therefore sought to determine the progression-free survival (PFS) and overall survival (OS) for patients with ovarian carcinosarcoma treated at our institution with different first-line ...

Last Updated: 31 Dec 1969

Go To URL
Clinical Significance of Programmed Death Ligand‑1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma.
 

Author(s): Jun Zhu, Hao Wen, Xingzhu Ju, Rui Bi, Wenjia Zuo, Xiaohua Wu

Journal:

 

Ovarian carcinosarcoma (OCS) accounts for high mortality and lacks effective therapeutic methods. So far, we lack reliable biomarkers capable of predicting the risk of aggressive course of the disease. Programmed death ligand-1 (PD-L1) is expressed in various tumors, and antibodies ...

Last Updated: 31 Dec 1969

Go To URL
Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study.
 

Author(s): Tadaaki Nishikawa, Kosei Hasegawa, Akira Yabuno, Hiroyuki Yoshida, Masanori Yasuda, Eito Kozawa, Keiichi Fujiwara

Journal: J Gynecol Oncol. 2017 Jan;28(1):e25.

 

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Ovarian carcinosarcoma" returned 1 free, full-text review articles on human participants. First 3 results:

Borderline mucinous cystic ovarian tumor with mural nodules (carcinosarcoma).
 

Author(s): Juei-Shan Chang, Ching-Chuang Chua, Chin-Cheng Lee

Journal: Ann Saudi Med. ;32(4):415-20.

 

Carcinosarcoma mural nodules arising form a mucinous ovarian neoplasm is very rare and only two published cases have been reported. We report a case of a 29-year-old female patient who suffered from severe lower abdominal pain unrelated to menstruation for 1 year. She came to our ...

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
 

Status: Not yet recruiting

Condition Summary: Ovarian Carcinosarcoma; Endometrial Carcinosarcoma

 

Last Updated: 27 Aug 2018

Go to URL
Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)_MITO 26
 

Status: Not yet recruiting

Condition Summary: Carcinosarcoma, Ovarian; Carcinosarcomas Uterine

 

Last Updated: 12 Dec 2016

Go to URL
Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
 

Status: Not yet recruiting

Condition Summary: Ovarian Cancer; Ovarian Neoplasms; Ovarian Carcinosarcoma; Ovarian Serous Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Fallopian Tube Cancer; Fallopian Tube Neoplasms; Primary Peritoneal Carcinoma; Primary Peritoneal Serous Adenocarcinoma

 

Last Updated: 24 Aug 2018

Go to URL